Northern Trust Corp Aytu Biopharma, Inc Transaction History

Northern Trust Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.19 - $3.8 $292 - $5,848	-1,539 Reduced 3.2%	46,593 $9,000
Q2 2022 Aug 12, 2022	SELL	$0.46 - $1.08 $230 - $540	-500 Reduced 1.03%	48,132 $34,000
Q1 2022 May 13, 2022	SELL	$1.08 - $1.55 $227 - $327	-211 Reduced 0.43%	48,632 $53,000
Q4 2021 Feb 08, 2022	SELL	$1.35 - $2.95 $333 - $728	-247 Reduced 0.5%	48,843 $66,000
Q3 2021 Nov 15, 2021	BUY	$2.78 - $5.12 $5,640 - $10,388	2,029 Added 4.31%	49,090 $141,000
Q2 2021 Aug 13, 2021	SELL	$4.73 - $7.56 $785,553 - $1.26 Million	-166,079 Reduced 77.92%	47,061 $236,000
Q1 2021 May 12, 2021	BUY	$6.23 - $9.88 $1.02 Million - $1.62 Million	164,189 Added 335.42%	213,140 $1.62 Million
Q4 2020 Feb 11, 2021	BUY	$5.98 - $13.5 $292,726 - $660,838	48,951 New	48,951 $293,000

Ticker AYTU
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 62,432,700
Market Cap $91.2M
Description
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT f...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.